Behenic Acid

Behenic Acid

SCHEMBL190890

CCCCCCCCCCCCCCCCCCCCCC(=O)O.CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO

nearest known ligand 0.88

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.88
KDM4E B2RXH2 1/20 0.88
DUSP3 P51452 1/20 0.88
MEN1 O00255 1/20 0.88
KMT2A Q03164 1/20 0.88
DGKA P23743 1/20 0.74
FAAH O00519 2/20 0.62
MAPT P10636 1/20 0.61
PRKCA P17252 3/20 0.59
PRKCE Q02156 1/20 0.59
PRKCQ Q04759 1/20 0.59
PRKCD Q05655 1/20 0.59
ENPP2 Q13822 2/20 0.58
LPAR6 P43657 1/20 0.58
LPAR1 Q92633 1/20 0.58
LPAR4 Q99677 1/20 0.58
LPAR5 Q9H1C0 1/20 0.58
LPAR2 Q9HBW0 1/20 0.58
LPAR3 Q9UBY5 1/20 0.58
PAM P19021 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Monoctanoin Component B SCHEMBL8394660 1.00 LMNA (0.88) LMNAKDM4EDUSP3MEN1KMT2A
Decanoic Acid SCHEMBL4663166 1.00 LMNA (0.88) LMNAKDM4EDUSP3MEN1KMT2A
Glycerol Monolaurate SCHEMBL2241699 1.00 LMNA (0.88) LMNAKDM4EDUSP3MEN1KMT2A
Palmitic Acid SCHEMBL23850779 1.00 LMNA (0.88) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL1960888 1.00 LMNA (0.88) LMNAKDM4EDUSP3MEN1KMT2A
Monoctanoin Component A SCHEMBL25311832 1.00 LMNA (0.88) LMNAKDM4EDUSP3MEN1KMT2A
Nonadecanoic Acid SCHEMBL2028549 1.00 LMNA (0.88) LMNAKDM4EDUSP3MEN1KMT2A
Heptadecanoic Acid SCHEMBL2006352 1.00 LMNA (0.88) LMNAKDM4EDUSP3MEN1KMT2A
Glyceryl Monostearate SCHEMBL365822 1.00 LMNA (0.88) LMNAKDM4EDUSP3MEN1KMT2A
Glyceryl Monostearate SCHEMBL16684813 1.00 LMNA (0.88) LMNAKDM4EDUSP3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 597 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116211742-A Microemulsion and preparation method thereof 上海林清轩生物科技有限公司 2023-06-06 CN claimed
WO-2018055641-A1 ORAL MODIFIED RELEASE FORMULATIONS RUBICON RESEARCH PRIVATE LIMITED (IN) 2018-03-29 WO claimed
US-20170128379-A1 MODIFIED RELEASE PHARMACEUTICAL PREPARATIONS RUBICON RESEARCH PRIVATE LIMITED (IN) 2017-05-11 US claimed
WO-2016001937-A2 MODIFIED RELEASE PHARMACEUTICAL PREPARATIONS RUBICON RESEARCH PRIVATE LIMITED (IN) 2016-01-07 WO claimed
US-20120093738-A1 TASTE-MASKED ORAL FORMULATIONS OF INFLUENZA ANTIVIRALS RUBICON RESEARCH PRIVATE LIMITED (IN) 2012-04-19 US claimed
WO-2011030351-A2 TASTE - MASKED PHARMACEUTICAL COMPOSITIONS RUBICON RESEARCH PRIVATE LIMITED (IN) 2011-03-17 WO claimed
WO-2010143207-A1 TASTE-MASKED ORAL FORMULATIONS OF INFLUENZA ANTIVIRALS RUBICON RESEARCH PRIVATE LIMITED (IN) 2010-12-16 WO claimed
WO-2010116385-A2 PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING UNPLEASANT TASTE RUBICON RESEARCH PRIVATE LIMITED (IN) 2010-10-14 WO claimed
WO-2010046933-A2 PHARMACEUTICAL COMPOSITIONS OF TASTE-MASKED LINEZOLID RUBICON RESEARCH PRIVATE LIMITED (IN) 2010-04-29 WO claimed
WO-2010044108-A2 CONTROLLED RELEASE FORMULATIONS OF ROPINIROLE RUBICON RESEARCH PRIVATE LIMITED (IN) 2010-04-22 WO claimed
WO-2009078034-A2 ORAL DISINTEGRATING TABLETS OF ROPINIROLE HYDROCHLORIDE RUBICON RESEARCH PRIVATE LIMITED (IN) 2009-06-25 WO claimed
US-5888533-A Non-polymeric sustained release delivery system ATRIX LABORATORIES, INC. (US) 1999-03-30 US claimed
US-12576017-B2 Sunscreen composition with enhanced photoprotection EDGEWELL PERSONAL CARE BRANDS, LLC (US) 2026-03-17 US disclosed
US-12546710-B2 Detection of a personal care composition based on infrared radiation EDGEWELL PERSONAL CARE BRANDS, LLC (US) 2026-02-10 US disclosed
US-20250367107-A1 SUNSCREEN COMPOSITION INCLUDING A SALICYLATE AND PONGAMIA PINNATA SEED EXTRACT EDGEWELL PERSONAL CARE BRANDS LLC (US) 2025-12-04 US disclosed
EP-4647131-A2 PERSONAL CARE COMPOSITION AND PERSONAL CARE PRODUCT Edgewell Personal Care Brands, LLC (US) 2025-11-12 EP disclosed
EP-0140921-A1 PHARMACEUTICAL COMPOSITIONS. BLOCH MAURICE 1985-05-15 EP disclosed
WO-1984003623-A1 PHARMACEUTICAL COMPOSITIONS BLOCH MAURICE 1984-09-27 WO disclosed
US-4434153-A Drug delivery system comprising a reservoir containing a plurality of tiny pills ALZA CORPORATION (US) 1984-02-28 US disclosed
US-4104370-A Method of treating magnesium/potassium depletion SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1978-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12546710-B2 Detection of a personal care composition based on infrared radiation DDR1, XPA, ERCC1 LMNA 1935/4885KDM4E 2884/4885DUSP3 2541/4885
US-12576017-B2 Sunscreen composition with enhanced photoprotection TELO2, AS3MT, TYR LMNA 3703/4885KDM4E 1010/4885DUSP3 2219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.